On the public citation graph

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation A Randomized Controlled Trial

https://doi.org/10.1001/jama.296.1.47
0 signed · 1340 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.166.15.1561openalex-snapshot
Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist
inferredcites →https://doi.org/10.1001/archpsyc.1978.01770280111012openalex-snapshot
Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine
inferredcites →https://doi.org/10.1001/archpsyc.1986.01800030107013openalex-snapshot
Signs and Symptoms of Tobacco Withdrawal
inferredcites →https://doi.org/10.1001/jama.1996.03540080019009openalex-snapshot
Cigarette Smoking Among Adults—United States, 1994
inferredcites →https://doi.org/10.1001/jama.294.2.172openalex-snapshot
Cigarette Smoking Among Adults--United States, 2003
inferredcites →https://doi.org/10.1001/jama.296.1.56openalex-snapshot
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
inferredcites →https://doi.org/10.1001/jama.296.1.64openalex-snapshot
Effect of Maintenance Therapy With Varenicline on Smoking Cessation A Randomized Controlled Trial
inferredcites →https://doi.org/10.1016/j.bmcl.2005.08.035openalex-snapshot
3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation
inferredcites →https://doi.org/10.1016/s0014-2999(00)00122-9openalex-snapshot
Role of dopamine in the behavioural actions of nicotine related to addiction
inferredcites →https://doi.org/10.1016/s0026-895x(25)09896-7openalex-snapshot
Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit.
inferredcites →https://doi.org/10.1016/s1098-3015(10)62876-8openalex-snapshot
PSM2 CONFIRMATORY FACTOR ANALYSIS AND RELIABILITY OF THE “SMOKING EFFECTS INVENTORY”
inferredcites →https://doi.org/10.1016/s1098-3015(10)62877-xopenalex-snapshot
PSM3 CONFIRMATORY VALIDATION OF THE BRIEF QUESTIONNAIRE OF SMOKING URGES
inferredcites →https://doi.org/10.1037//1064-1297.6.3.331openalex-snapshot
Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.
inferredcites →https://doi.org/10.1038/382255a0openalex-snapshot
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs
inferredcites →https://doi.org/10.1038/nature03694openalex-snapshot
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
inferredcites →https://doi.org/10.1046/j.1365-2796.2003.01185.xopenalex-snapshot
A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation
inferredcites →https://doi.org/10.1056/nejm199903043400903openalex-snapshot
A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation
inferredcites →https://doi.org/10.1067/mcp.2001.115750openalex-snapshot
Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo‐controlled study
inferredcites →https://doi.org/10.1080/14622200020032051openalex-snapshot
Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings
inferredcites →https://doi.org/10.1080/14622200123249openalex-snapshot
Individual differences in smoking reward from de-nicotinized cigarettes
inferredcites →https://doi.org/10.1080/14622200124218openalex-snapshot
Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings
inferredcites →https://doi.org/10.1080/14622200410001734067openalex-snapshot
Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials
inferredcites →https://doi.org/10.1093/acrefore/9780199975839.013.104openalex-snapshot
Diagnostic and Statistical Manual of Mental Disorders
inferredcites →https://doi.org/10.1111/j.1360-0443.1991.tb01879.xopenalex-snapshot
The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
inferredcites →https://doi.org/10.1126/science.1099420openalex-snapshot
Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization
inferredcites →https://doi.org/10.1176/appi.ajp.162.8.1432openalex-snapshot
Medication Development for Addictive Disorders: The State of the Science
inferredcites →https://doi.org/10.1177/002013240004501006openalex-snapshot
Treating Tobacco Use and Dependence: An Introduction to the Us Public Health Service Clinical Practice Guideline
inferredcites →https://doi.org/10.1185/030079905x43712openalex-snapshot
Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4632941openalex-extracted
Association between Nicotine Metabolite Ratio and Smoking Cessation Medications in Chinese Male Smokers - Results of the China National Tobacco Cessation Cohort Study
inferred← citeshttps://doi.org/10.1001/archinte.166.15.1561openalex-snapshot
Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist
inferred← citeshttps://doi.org/10.1001/archinte.167.16.1791openalex-snapshot
A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care
inferred← citeshttps://doi.org/10.1001/archinternmed.2011.138openalex-snapshot
Use of Varenicline for 4 Weeks Before Quitting Smoking
inferred← citeshttps://doi.org/10.1001/archinternmed.2011.72openalex-snapshot
Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome
inferred← citeshttps://doi.org/10.1001/jama.2008.982openalex-snapshot
A 51-Year-Old Woman With Bipolar Disorder Who Wants to Quit Smoking
inferred← citeshttps://doi.org/10.1001/jama.2012.13043openalex-snapshot
Strategies to Help a Smoker Who Is Struggling to Quit
inferred← citeshttps://doi.org/10.1001/jama.2013.283185openalex-snapshot
Combination Varenicline and Bupropion SR for Tobacco-Dependence Treatment in Cigarette Smokers
inferred← citeshttps://doi.org/10.1001/jama.2014.7195openalex-snapshot
Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation
inferred← citeshttps://doi.org/10.1001/jama.2015.19284openalex-snapshot
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks
inferred← citeshttps://doi.org/10.1001/jama.2015.280openalex-snapshot
Effect of Varenicline on Smoking Cessation Through Smoking Reduction
inferred← citeshttps://doi.org/10.1001/jama.2021.15333openalex-snapshot
Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation
inferred← citeshttps://doi.org/10.1001/jama.296.1.64openalex-snapshot
Effect of Maintenance Therapy With Varenicline on Smoking Cessation A Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1001/jama.296.1.94openalex-snapshot
Varenicline for Smoking Cessation
inferred← citeshttps://doi.org/10.1001/jama.296.21.2555-aopenalex-snapshot
Efficacy of Varenicline for Smoking Cessation
inferred← citeshttps://doi.org/10.1001/jama.296.21.2555-bopenalex-snapshot
Efficacy of Varenicline for Smoking Cessation—Reply
inferred← citeshttps://doi.org/10.1001/jamainternmed.2014.6916openalex-snapshot
Increasing Varenicline Dose in Smokers Who Do Not Respond to the Standard Dosage
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.0951openalex-snapshot
Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.17709openalex-snapshot
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.41731openalex-snapshot
Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence
inferred← citeshttps://doi.org/10.1001/jamapediatrics.2019.3553openalex-snapshot
Efficacy and Safety of Varenicline for Adolescent Smoking Cessation
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2013.678openalex-snapshot
Effects of Varenicline and Bupropion Sustained-Release Use Plus Intensive Smoking Cessation Counseling on Prolonged Abstinence From Smoking and on Depression, Negative Affect, and Other Symptoms of Nicotine Withdrawal
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2017.3544openalex-snapshot
Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2023.1691openalex-snapshot
Effect of a Tobacco Cessation Intervention Incorporating Weight Management for Adults With Serious Mental Illness
inferred← citeshttps://doi.org/10.1002/0471266949.bmc200openalex-snapshot
Drug Discovery in Non‐Life‐Threatening Disorders: Erectile Dysfunction, Insomnia, and Smoking Cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd000031.pub3openalex-snapshot
Antidepressants for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd000031.pub4openalex-snapshot
Antidepressants for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd000031.pub5openalex-snapshot
Antidepressants for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd000031.pub6openalex-snapshot
Antidepressants for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd004305.pub3openalex-snapshot
Healthcare financing systems for increasing the use of tobacco dependence treatment
inferred← citeshttps://doi.org/10.1002/14651858.cd004305.pub5openalex-snapshot
Healthcare financing systems for increasing the use of tobacco dependence treatment
inferred← citeshttps://doi.org/10.1002/14651858.cd004306.pub5openalex-snapshot
Interventions for smokeless tobacco use cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub2openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub3openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub4openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub5openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub6openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub7openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub8openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006103.pub9openalex-snapshot
Nicotine receptor partial agonists for smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006219.pub2openalex-snapshot
Interventions for preventing weight gain after smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006219.pub3openalex-snapshot
Interventions for preventing weight gain after smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd006219.pub4openalex-snapshot
Interventions for preventing weight gain after smoking cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd009329.pub2openalex-snapshot
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
inferred← citeshttps://doi.org/10.1002/14651858.cd011823.pub2openalex-snapshot
Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers
inferred← citeshttps://doi.org/10.1002/9780470479216.corpsy0014openalex-snapshot
Addiction
inferred← citeshttps://doi.org/10.1002/9780470696330.ch1openalex-snapshot
Smoking Cessation
inferred← citeshttps://doi.org/10.1002/9780470697603.ch4openalex-snapshot
Smoking Cessation
inferred← citeshttps://doi.org/10.1002/9780470710449.ch17openalex-snapshot
Addictive Disorders in Cardiovascular Medicine
inferred← citeshttps://doi.org/10.1002/9780470710449.ch32openalex-snapshot
Pharmacological Therapeutics for Detoxification in Addictive Disorders
inferred← citeshttps://doi.org/10.1002/9780470710449.ch33openalex-snapshot
Pharmacological Therapeutics for Relapse Reduction in Addictive Disorders
inferred← citeshttps://doi.org/10.1002/9781118023150.ch15openalex-snapshot
Nicotine Discrimination in Humans
inferred← citeshttps://doi.org/10.1002/9781118101056.refsopenalex-snapshot
References
inferred← citeshttps://doi.org/10.1002/9781118133880.hop209007openalex-snapshot
Nicotine Dependence
inferred← citeshttps://doi.org/10.1002/9781118281796.ch4openalex-snapshot
Breathing Easier: Respiratory Disease in the Older Adult
inferred← citeshttps://doi.org/10.1002/9781118312513.ch8openalex-snapshot
Lung Cancer Prevention
inferred← citeshttps://doi.org/10.1002/9781118753378.ch113openalex-snapshot
Pharmacological Treatment of Substance Abuse Disorders
inferred← citeshttps://doi.org/10.1002/9781118753378.ch81openalex-snapshot
Substance‐Related and Addictive Disorders: Tobacco‐Related Disorders
inferred← citeshttps://doi.org/10.1002/9781119376354.ch5openalex-snapshot
Construct Validity and Criterion Validity
inferred← citeshttps://doi.org/10.1002/9781119376354.ch6openalex-snapshot
Responsiveness and Sensitivity
inferred← citeshttps://doi.org/10.1002/9781444309768.ch65openalex-snapshot
Peripheral Arterial Disease
inferred← citeshttps://doi.org/10.1002/ajmg.b.30978openalex-snapshot
Pharmacogenetics of smoking cessation therapy
inferred← citeshttps://doi.org/10.1002/ccd.21401openalex-snapshot
Optimal risk factor modification and medical management of the patient with peripheral arterial disease
inferred← citeshttps://doi.org/10.1002/ccd.23373openalex-snapshot
2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (Updating the 2005 guideline)
inferred← citeshttps://doi.org/10.1002/cncr.23061openalex-snapshot
Emerging issues in smoking among adolescent and adult cancer survivors: a comprehensive review.
inferred← citeshttps://doi.org/10.1002/dta.1707openalex-snapshot
Pharmacokinetics of cytisine, an α4β2 nicotinic receptor partial agonist, in healthy smokers following a single dose
inferred← citeshttps://doi.org/10.1002/hed.25708openalex-snapshot
“Cold turkey” or pharmacotherapy: Examination of tobacco cessation methods tried among smokers prior to developing head and neck cancer
inferred← citeshttps://doi.org/10.1002/hup.1113openalex-snapshot
Varenicline does not increase serum BDNF levels in patients with nicotine dependence
inferred← citeshttps://doi.org/10.1002/hup.2665openalex-snapshot
Effects of galantamine on smoking behavior and cognitive performance in treatment‐seeking smokers prior to a quit attempt
inferred← citeshttps://doi.org/10.1002/mds.25594openalex-snapshot
Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
inferred← citeshttps://doi.org/10.1002/med.21666openalex-snapshot
Recent advances with 5‐HT3 modulators for neuropsychiatric and gastrointestinal disorders
inferred← citeshttps://doi.org/10.1002/pds.2003openalex-snapshot
Utilization of the smoking cessation medicine varenicline: an intensive post‐marketing study in New Zealand
inferred← citeshttps://doi.org/10.1002/pds.3400openalex-snapshot
The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey
inferred← citeshttps://doi.org/10.1002/pds.4926openalex-snapshot
Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research
inferred← citeshttps://doi.org/10.1002/phar.2073openalex-snapshot
Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking
inferred← citeshttps://doi.org/10.1002/psp4.12645openalex-snapshot
Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers
inferred← citeshttps://doi.org/10.1002/rcm.4976openalex-snapshot
Electron impact mass spectral study of halogenated N ‐acetyl‐ and N ‐propionylcytisines
inferred← citeshttps://doi.org/10.1002/wps.20905openalex-snapshot
Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double‐blind randomized controlled trial
inferred← citeshttps://doi.org/10.1007/164_2019_252openalex-snapshot
Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence
inferred← citeshttps://doi.org/10.1007/7355_2014_56openalex-snapshot
Nicotinic Acetylcholine Receptor Modulators
inferred← citeshttps://doi.org/10.1007/7854_2009_20openalex-snapshot
Neural Substrates of Psychostimulant Withdrawal-Induced Anhedonia
inferred← citeshttps://doi.org/10.1007/7854_2009_29openalex-snapshot
Novel Pharmacological Approaches to Drug Abuse Treatment
inferred← citeshttps://doi.org/10.1007/7854_2011_132openalex-snapshot
Translational Approaches to Medication Development
inferred← citeshttps://doi.org/10.1007/7854_2020_134openalex-snapshot
Nicotinic Receptors Underlying Nicotine Dependence: Evidence from Transgenic Mouse Models
inferred← citeshttps://doi.org/10.1007/7854_2025_598openalex-snapshot
Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models
inferred← citeshttps://doi.org/10.1007/978-0-387-85960-6_12openalex-snapshot
Nicotine Dependence and Cardiovascular Diseases: Biobehavioral and Psychosocial Correlates
inferred← citeshttps://doi.org/10.1007/978-1-4419-0338-9_19openalex-snapshot
Nicotine
inferred← citeshttps://doi.org/10.1007/978-1-4419-0338-9_42openalex-snapshot
Unhealthy Alcohol and Drug Use in Primary Care
inferred← citeshttps://doi.org/10.1007/978-1-4419-0338-9_49openalex-snapshot
Nicotine
inferred← citeshttps://doi.org/10.1007/978-1-4614-3375-0_10openalex-snapshot
Nicotine
inferred← citeshttps://doi.org/10.1007/978-1-4614-9509-3_7openalex-snapshot
Genetics of Substance Use Disorders
inferred← citeshttps://doi.org/10.1007/978-1-4939-0342-9_18openalex-snapshot
The Prevention and Treatment of Coronary Artery Disease in Kidney Transplant Recipients
inferred← citeshttps://doi.org/10.1007/978-1-4939-0986-5_15openalex-snapshot
Tobacco Cessation
inferred← citeshttps://doi.org/10.1007/978-1-4939-1167-7_15openalex-snapshot
Neuronal Nicotinic Acetylcholine Receptors in Reward and Addiction
inferred← citeshttps://doi.org/10.1007/978-1-59745-197-0_17openalex-snapshot
Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions
inferred← citeshttps://doi.org/10.1007/978-1-59745-357-8_8openalex-snapshot
Pharmacological Therapy: Novel Approaches
inferred← citeshttps://doi.org/10.1007/978-1-59745-357-8_9openalex-snapshot
Smoking Cessation
inferred← citeshttps://doi.org/10.1007/978-1-60327-250-6_23openalex-snapshot
Management of Disease in Women with Diabetes
inferred← citeshttps://doi.org/10.1007/978-1-60761-524-8_5openalex-snapshot
Lung Cancer Prevention
inferred← citeshttps://doi.org/10.1007/978-1-60761-673-3_1openalex-snapshot
Mortality in COPD: The Role of Comorbidities
inferred← citeshttps://doi.org/10.1007/978-1-84628-502-8_29openalex-snapshot
Treatment of Tobacco Dependency
inferred← citeshttps://doi.org/10.1007/978-1-84628-502-8_53openalex-snapshot
Pharmacotherapy in Prevention and Rehabilitation
inferred← citeshttps://doi.org/10.1007/978-1-907673-52-8_6openalex-snapshot
The Future of COPD
inferred← citeshttps://doi.org/10.1007/978-1-908517-61-6_6openalex-snapshot
The Future of COPD
inferred← citeshttps://doi.org/10.1007/978-3-030-28328-5_28openalex-snapshot
Lower Extremity Ischemia
inferred← citeshttps://doi.org/10.1007/978-3-030-36391-8_15openalex-snapshot
Nicotine and Tobacco
inferred← citeshttps://doi.org/10.1007/978-3-030-42825-9_13-1openalex-snapshot
Disorders Due to Substance Use: Nicotine (Including Tobacco and Vaping)
inferred← citeshttps://doi.org/10.1007/978-3-030-51366-5_13openalex-snapshot
Disorders Due to Substance Use: Nicotine
inferred← citeshttps://doi.org/10.1007/978-3-030-62059-2_350openalex-snapshot
Agents for Treatment of Withdrawal and Dependency: Varenicline
inferred← citeshttps://doi.org/10.1007/978-3-030-63549-7_7openalex-snapshot
Sex Differences in Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1007/978-3-030-95734-6_8openalex-snapshot
What Is New in the Non-pharmacological Approaches to Hypertension Control
inferred← citeshttps://doi.org/10.1007/978-3-031-16594-8_2openalex-snapshot
Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2
inferred← citeshttps://doi.org/10.1007/978-3-031-22483-6_140-1openalex-snapshot
Effect of Gender on Pulmonary Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-22483-6_98-1openalex-snapshot
Nicotine Dependence and Recommendations for Smoking Cessation
inferred← citeshttps://doi.org/10.1007/978-3-031-57159-6_33-1openalex-snapshot
Neurotransmitters and Neural Pathways
inferred← citeshttps://doi.org/10.1007/978-3-031-57159-6_59-1openalex-snapshot
Pharmacotherapy for Nicotine and Tobacco Use Disorders
inferred← citeshttps://doi.org/10.1007/978-3-032-17118-4_8openalex-snapshot
Smoking Cessation
inferred← citeshttps://doi.org/10.1007/978-3-032-29397-8_15openalex-snapshot
Tobacco Use, Smoking Cessation, and Perioperative Risk
inferred← citeshttps://doi.org/10.1007/978-3-319-13117-7_111openalex-snapshot
Neural Activity of Cues Associated with Smoking after 24-Hour Smoking Abstinence and After 7-Days of Treatment and Smoking Abstinence
inferred← citeshttps://doi.org/10.1007/978-3-319-13482-6_5openalex-snapshot
Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation Medications
inferred← citeshttps://doi.org/10.1007/978-3-319-23150-1_2openalex-snapshot
Therapeutic Vaccines for Treating Nicotine Addiction
inferred← citeshttps://doi.org/10.1007/978-3-319-56015-1_350-1openalex-snapshot
Agents for Treatment of Withdrawal and Dependency: Varenicline
inferred← citeshttps://doi.org/10.1007/978-3-540-68748-1_33openalex-snapshot
Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen
inferred← citeshttps://doi.org/10.1007/978-3-540-69219-5_2openalex-snapshot
Neue Arzneimittel 2007
inferred← citeshttps://doi.org/10.1007/978-3-540-69248-5_12openalex-snapshot
Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties
inferred← citeshttps://doi.org/10.1007/978-3-540-69248-5_13openalex-snapshot
Discriminative Stimulus Effects of Nicotine in Humans
inferred← citeshttps://doi.org/10.1007/978-3-540-69248-5_17openalex-snapshot
Pharmacotherapy for Tobacco Dependence
inferred← citeshttps://doi.org/10.1007/978-3-540-69248-5_5openalex-snapshot
Magnetic Resonance Imaging Studies of Cigarette Smoking
inferred← citeshttps://doi.org/10.1007/978-3-540-73232-7_25openalex-snapshot
Smoking Cessation
inferred← citeshttps://doi.org/10.1007/978-3-540-73309-6_13openalex-snapshot
Medikamentöse Behandlung des Rauchers
inferred← citeshttps://doi.org/10.1007/978-3-540-78358-9_18openalex-snapshot
Partielle Agonisten nikotinerger Acetylcholin-Rezeptoren zur Rauchentwöhnung — ein Update
inferred← citeshttps://doi.org/10.1007/978-3-642-16920-5_42openalex-snapshot
Vaskuläre Erkrankungen
inferred← citeshttps://doi.org/10.1007/978-3-642-19844-1_58openalex-snapshot
Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen
inferred← citeshttps://doi.org/10.1007/978-3-642-27772-6_322-2openalex-snapshot
Nicotine Dependence and Its Treatment
inferred← citeshttps://doi.org/10.1007/978-3-662-44768-0_149-1openalex-snapshot
Primärprävention und Sekundärprävention des Hirninfarkts
inferred← citeshttps://doi.org/10.1007/978-3-662-44768-0_149-2openalex-snapshot
Primärprävention und Sekundärprävention des Hirninfarkts
inferred← citeshttps://doi.org/10.1007/978-3-662-60676-6_149openalex-snapshot
Primärprävention und Sekundärprävention des Hirninfarkts
inferred← citeshttps://doi.org/10.1007/978-88-470-5322-9_17openalex-snapshot
Nicotine and Tobacco
inferred← citeshttps://doi.org/10.1007/978-90-313-6614-9_90openalex-snapshot
NHG-Standaard Stoppen met roken
inferred← citeshttps://doi.org/10.1007/978-90-313-7249-2_6openalex-snapshot
6 Roken
inferred← citeshttps://doi.org/10.1007/978-90-313-8279-8_52openalex-snapshot
NHG-Standaard Stoppen met roken
inferred← citeshttps://doi.org/10.1007/978-90-481-8553-5_18openalex-snapshot
Smoking and Mental Disorders: Focus on Neuroprotection
inferred← citeshttps://doi.org/10.1007/978-94-007-4707-4_68openalex-snapshot
Neuroscience Perspectives on Addiction: Overview
inferred← citeshttps://doi.org/10.1007/978-981-10-3053-6_1openalex-snapshot
Medical Management of Lower Extremity Peripheral Artery Disease
inferred← citeshttps://doi.org/10.1007/bf03262382openalex-snapshot
Assessing Psychiatric Adverse Effects during Clinical Drug Development
inferred← citeshttps://doi.org/10.1007/bf03320849openalex-snapshot
Análisis coste-efectividad de vareniclina (Champix®) frente a los parches de nicotina en el tratamiento del tabaquismo en México
inferred← citeshttps://doi.org/10.1007/s00210-025-04178-9openalex-snapshot
New drugs and their performance 10 years after approval: a systematic analysis
inferred← citeshttps://doi.org/10.1007/s00213-006-0504-2openalex-snapshot
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine
inferred← citeshttps://doi.org/10.1007/s00213-007-1041-3openalex-snapshot
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt
inferred← citeshttps://doi.org/10.1007/s00213-008-1335-0openalex-snapshot
Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats
inferred← citeshttps://doi.org/10.1007/s00213-008-1358-6openalex-snapshot
Role of β2-containing nicotinic acetylcholine receptors in auditory event-related potentials
inferred← citeshttps://doi.org/10.1007/s00213-009-1488-5openalex-snapshot
Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice
inferred← citeshttps://doi.org/10.1007/s00213-009-1739-5openalex-snapshot
The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats
inferred← citeshttps://doi.org/10.1007/s00213-010-1816-9openalex-snapshot
Varenicline’s effects on acute smoking behavior and reward and their association with subsequent abstinence
inferred← citeshttps://doi.org/10.1007/s00213-010-1932-6openalex-snapshot
Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature
inferred← citeshttps://doi.org/10.1007/s00213-010-2024-3openalex-snapshot
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration
inferred← citeshttps://doi.org/10.1007/s00213-010-2160-9openalex-snapshot
A preliminary investigation of varenicline for heavy drinking smokers
inferred← citeshttps://doi.org/10.1007/s00213-011-2213-8openalex-snapshot
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control
inferred← citeshttps://doi.org/10.1007/s00213-011-2327-zopenalex-snapshot
Varenicline effects on craving, cue reactivity, and smoking reward
inferred← citeshttps://doi.org/10.1007/s00213-011-2585-9openalex-snapshot
Effect of fenfluramine on reinstatement of food seeking in female and male rats: implications for the predictive validity of the reinstatement model
inferred← citeshttps://doi.org/10.1007/s00213-012-2682-4openalex-snapshot
Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats
inferred← citeshttps://doi.org/10.1007/s00213-012-2698-9openalex-snapshot
Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokers
inferred← citeshttps://doi.org/10.1007/s00213-012-2700-6openalex-snapshot
The effects of varenicline on attention and inhibitory control among treatment-seeking smokers
inferred← citeshttps://doi.org/10.1007/s00213-012-2716-yopenalex-snapshot
Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice
inferred← citeshttps://doi.org/10.1007/s00213-012-2717-xopenalex-snapshot
Varenicline decreases alcohol consumption in heavy-drinking smokers
inferred← citeshttps://doi.org/10.1007/s00213-013-3145-2openalex-snapshot
Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration
inferred← citeshttps://doi.org/10.1007/s00213-013-3202-xopenalex-snapshot
Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study
inferred← citeshttps://doi.org/10.1007/s00213-013-3351-yopenalex-snapshot
Rhodiola rosea L. extract and its active compound salidroside antagonized both induction and reinstatement of nicotine place preference in mice
inferred← citeshttps://doi.org/10.1007/s00213-013-3364-6openalex-snapshot
An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation
inferred← citeshttps://doi.org/10.1007/s00213-013-3420-2openalex-snapshot
Perceived Medication Assignment during a Placebo-Controlled Laboratory Study of Varenicline: Temporal Associations of Treatment Expectancies with Smoking-Related Outcomes
inferred← citeshttps://doi.org/10.1007/s00213-014-3519-0openalex-snapshot
Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings
inferred← citeshttps://doi.org/10.1007/s00213-014-3619-xopenalex-snapshot
The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors
inferred← citeshttps://doi.org/10.1007/s00213-014-3732-xopenalex-snapshot
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline
inferred← citeshttps://doi.org/10.1007/s00213-015-4067-yopenalex-snapshot
The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats
inferred← citeshttps://doi.org/10.1007/s00213-017-4667-9openalex-snapshot
Effects of varenicline on alcohol cue reactivity in heavy drinkers
inferred← citeshttps://doi.org/10.1007/s00213-017-4721-7openalex-snapshot
Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo
inferred← citeshttps://doi.org/10.1007/s00213-017-4736-0openalex-snapshot
Effects of menthol and its interaction with nicotine-conditioned cue on nicotine-seeking behavior in rats
inferred← citeshttps://doi.org/10.1007/s00213-018-4853-4openalex-snapshot
Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats
inferred← citeshttps://doi.org/10.1007/s00213-019-5174-yopenalex-snapshot
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats
inferred← citeshttps://doi.org/10.1007/s00213-020-05451-wopenalex-snapshot
The effect of varenicline on mood and cognition in smokers with HIV
inferred← citeshttps://doi.org/10.1007/s00213-020-05713-7openalex-snapshot
The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure
inferred← citeshttps://doi.org/10.1007/s00213-022-06072-1openalex-snapshot
Understanding the stimulus effects of nicotine and bupropion in a drug-drug discriminated goal-tracking task
inferred← citeshttps://doi.org/10.1007/s00213-024-06556-2openalex-snapshot
Changes in distinct brain systems identified with fMRI during smoking cessation treatment with varenicline: a review
inferred← citeshttps://doi.org/10.1007/s00228-008-0530-6openalex-snapshot
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers
inferred← citeshttps://doi.org/10.1007/s00228-012-1220-yopenalex-snapshot
Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres
inferred← citeshttps://doi.org/10.1007/s00439-012-1143-9openalex-snapshot
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes
inferred← citeshttps://doi.org/10.1007/s00540-006-0483-9openalex-snapshot
Tobacco control for anesthesiologists
inferred← citeshttps://doi.org/10.1007/s10198-011-0333-zopenalex-snapshot
Assessing preferences for improved smoking cessation medications: a discrete choice experiment
inferred← citeshttps://doi.org/10.1007/s10354-008-0636-6openalex-snapshot
Vareniclin – medikamentöse Therapie der Tabakabhängigkeit
inferred← citeshttps://doi.org/10.1007/s10389-011-0476-5openalex-snapshot
Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s10405-008-0255-3openalex-snapshot
Tabakentwöhnung
inferred← citeshttps://doi.org/10.1007/s10552-010-9507-8openalex-snapshot
A bupropion smoking cessation clinical trial for cancer patients
inferred← citeshttps://doi.org/10.1007/s10571-007-9149-xopenalex-snapshot
Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking
inferred← citeshttps://doi.org/10.1007/s11011-012-9297-7openalex-snapshot
The effects of vasopressin and oxytocin on methamphetamine–induced place preference behaviour in rats
inferred← citeshttps://doi.org/10.1007/s11033-020-06009-xopenalex-snapshot
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
inferred← citeshttps://doi.org/10.1007/s11469-007-9090-8openalex-snapshot
Varenicline: A Novel Drug for Smoking Cessation
inferred← citeshttps://doi.org/10.1007/s11606-007-0133-4openalex-snapshot
Update in Addiction Medicine for the Generalist
inferred← citeshttps://doi.org/10.1007/s11606-008-0823-6openalex-snapshot
Update in New Medications for Primary Care
inferred← citeshttps://doi.org/10.1007/s11606-009-0926-8openalex-snapshot
Mood, Side-effects and Smoking Outcomes Among Persons With and Without Probable Lifetime Depression Taking Varenicline
inferred← citeshttps://doi.org/10.1007/s11606-025-09370-4openalex-snapshot
EBM BLS: Varenicline Improves Electronic Cigarette Quit Success Rate
showing the first 200 of 1312 · page through all 1312
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.